The role of microhomology-mediated end joining in Fanconi anemia pathogenesis
The role of microhomology-mediated end joining in Fanconi anemia pathogenesis
批准号:
10580006
负责人:
Neil Johnson
金额:
$46.75万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-02-01 至 2024-01-31
关键词:
AdultAllelesAmino AcidsAnemiaAnimal ModelAshkenazimBRCA1 geneBRCA2 geneBiologicalBiological AssayBone marrow failureCRISPR/Cas technologyCell LineCellsChemicalsChildCoiled-Coil DomainComplexDNADNA Double Strand BreakDNA RepairDNA Repair GeneDNA Repair PathwayDNA-Directed DNA PolymeraseDataDefectDevelopmentDiseaseEmbryoEmbryonic DevelopmentEquilibriumEtiologyExcisionFanconi&aposs AnemiaFlow CytometryFunctional disorderGenomic InstabilityHealthHematologyHematopoiesisHematopoietic stem cellsHereditary Breast and Ovarian Cancer SyndromeHumanHyperactivityImmunofluorescence MicroscopyIncidenceIndividualInterventionKnockout MiceLaboratoriesLifeMeasuresMediatingMolecularMusMusculoskeletalMutationOncogenesOrganismPALB2 genePathogenesisPathologicPathway interactionsPatientsPhenotypePopulationProcessProteinsReporterResectedRoleSeveritiesSingle-Stranded DNASubgroupSymptomsTestingTransgenic AnimalsTransplantationWorkautosomecancer predispositiondevelopmental diseaseexperimental studygenetic approachhomologous recombinationinhibitorinsightleukemiamouse modelmutant mouse modelneonatal micenucleasep53-binding protein 1pre-clinicalprotein expressionrecombinational repairrecruitrepairedtherapeutic developmenttool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Children with Fanconi anemia (FA) demonstrate developmental disorders that include short stature,
musculoskeletal defects, cancer predisposition, bone marrow failure (BMF) and anemia. In a significant
proportion of cases, FA is associated with biallelic mutations in the hereditary breast and ovarian cancer (HBOC)
genes. Pre-clinical FA studies have largely relied on transgenic animal models. However, currently available FA
mouse models are born without developmental defects and hematological abnormalities have to be chemically
induced. Our laboratory has developed a new Brca1CC mutant mouse model with a 3-amino acid deletion in the
coiled-coil (CC) domain of Brca1 that specifically disrupts the Brca1-Palb2 association, resulting in loss of Rad51
loading and HR deficiency. Notably, Brca1CC homozygous mice are born at sub-Mendelian ratios, and neo-natal
mice demonstrate a range of phenotypes analogous to FA in humans, including short stature, BMF with severe
anemia, and adult mice develop leukemia. Therefore, Brca1CC mice closely resemble human FA and provide a
new tool to gain unprecedented insight into biological pathways that underpin FA etiology. Both homologous
recombination (HR) and microhomology-mediated end joining (MMEJ) are double stranded DNA break (DSB)
repair pathways that are initiated by DNA end resection, a process where DSBs are resected by nucleases to
form single stranded (ss)DNA regions. In preliminary data, we examined human FA patient cells, as well as
Brca1CC MEFs, for HR and MMEJ activity. Interestingly, while HR was lowered, MMEJ was hyperactivated in FA
cell lines. We now hypothesize that hyperactive DNA end resection and MMEJ promote the molecular
pathogenesis of FA. We will address the following Specific Aims: 1) identify DNA repair pathways that are
hyperactive in FA; 2) uncover mechanisms that promote FA embryonic development and pathogenesis; and 3)
examine the effects of MMEJ inhibition on FA pathogenesis. Collectively, the proposed experiments will yield
new insight into DNA repair mechanisms that promote genome instability and FA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer
-
批准号:10446399
-
项目类别:
-
资助金额:$43.01万
-
财政年份:2022
-
负责人:Neil Johnson
-
依托单位:
Assessing DNA Polymerase Theta as a Therapeutic Target in BRCA1 Mutant Cancer
-
批准号:10884036
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2022
-
负责人:Neil Johnson
-
依托单位:
Assessing DNA polymerase theta as a therapeutic target in BRCA1 mutant cancer
-
批准号:10579323
-
项目类别:
-
资助金额:$42.14万
-
财政年份:2022
-
负责人:Neil Johnson
-
依托单位:
Dissecting BRCA1-PALB2 Activity in DNA Repair and Development
-
批准号:10664883
-
项目类别:
-
资助金额:$38.66万
-
财政年份:2020
-
负责人:Neil Johnson
-
依托单位:
Dissecting BRCA1-PALB2 Activity in DNA Repair and Development
-
批准号:10229611
-
项目类别:
-
资助金额:$42.9万
-
财政年份:2020
-
负责人:Neil Johnson
-
依托单位:
Dissecting BRCA1-PALB2 Activity in DNA Repair and Development
-
批准号:10453625
-
项目类别:
-
资助金额:$40.83万
-
财政年份:2020
-
负责人:Neil Johnson
-
依托单位:
Dissecting BRCA1-PALB2 Activity in DNA Repair and Development
-
批准号:10388570
-
项目类别:
-
资助金额:$22.9万
-
财政年份:2020
-
负责人:Neil Johnson
-
依托单位:
The role of microhomology-mediated end joining in Fanconi anemia pathogenesis
-
批准号:10367981
-
项目类别:
-
资助金额:$45.41万
-
财政年份:2020
-
负责人:Neil Johnson
-
依托单位:
Compensatory mechanisms that promote homologous recombination in BRCA1 mutant cancers
-
批准号:10242152
-
项目类别:
-
资助金额:$42.78万
-
财政年份:2019
-
负责人:Neil Johnson
-
依托单位:
Compensatory mechanisms that promote homologous recombination in BRCA1 mutant cancers
-
批准号:9762056
-
项目类别:
-
资助金额:$41.49万
-
财政年份:2019
-
负责人:Neil Johnson
-
依托单位:
Compensatory mechanisms that promote homologous recombination in BRCA1 mutant cancers
-
批准号:9397651
-
项目类别:
-
资助金额:$41.86万
-
财政年份:2017
-
负责人:Neil Johnson
-
依托单位:
Identifying BRCA1 protein variants that provide resistance to therapy
-
批准号:9036352
-
项目类别:
-
资助金额:$23.29万
-
财政年份:2015
-
负责人:Neil Johnson
-
依托单位:
海外基金